D drug resistance in colon cancer stem cells. Cell Cycle 2008, 7(3):309-
D drug resistance in colon cancer stem cells. Cell Cycle 2008, 7(3):309-13. 100. Francipane M, Alea M, Lombardo Y, et al: Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 2008, 68(11):4022-5. 101. Eckford P, Sharom F: ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109(7):2989-3011.Liu et al. Journal of Translational Medicine 2011, 9:50 http://www.translational-medicine.com/content/9/1/Page 9 of102. Fletcher J, Haber M, Henderson M, et al: ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10(2):147-56. 103. Ding X, Wu J, Jiang C: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010, 86(17-18):631-7. 104. Shukla S, Wu C, Ambudkar S: Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008, 4(2):205-23. 105. Diehn M, Cho R, Lobo N, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458(7239):780-3. 106. Lomonaco S, Finniss S, Xiang C, et al: The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125(3):717-22. 107. Phillips T, McBride W, Pajonk F: The response of CD24(-/low)/CD44+ AviptadilMedChemExpress Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine) breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-85.doi:10.1186/1479-5876-9-50 Cite this article as: Liu et al.: Cancer stem cell subsets and their relationships. Journal of Translational Medicine 2011 9:50.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
Hou et al. Journal of PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 Translational Medicine 2011, 9:64 http://www.translational-medicine.com/content/9/1/RESEARCHOpen AccessInhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SUJinxuan Hou1,2, Jixin Dong3, Lijun Sun4, Liying Geng3, Jing Wang3, Jialin Zheng4, Yan Li2, Julia Bridge1, Steven H Hinrichs1 and Shi-Jian Ding1*AbstractBackground: c-Met is a receptor tyrosine kinase (RTK) that is over-expressed in a variety of cancers and involved in cell growth, invasion, metastasis and angiogenesis. In this study, we investigated the role of c-Met in rhabdomyosarcoma (RMS) using its small molecule inhibitor SU11274, which has been hypothesized to be a potential therapeutic target for RMS. Methods: The expression level of phosphorylated c-Met in RMS cell lines (RD, CW9019 and RH30) and tumor tissues was assessed by phospho-RTK array and immunohistochemistry, respectively. The inhibition effects of SU11274 on RMS cells were studied with regard to intracellular signaling, cell proliferation, cell cycle and cell migration. Results: A high level of phosphorylated c-Met was detected in 2 alveolar RMS cell lines (CW9019 and RH30) and 14 out of 24 RMS tissue samples, whereas relatively low levels of phospho-c-Met were observed in the embryonic RMS cell line (RD). The small molecule SU11274 could significantly reduce the phosphorylation of c-Met, resulting in inhibition of cell proliferation, G1 phase arrest of cell cycle and blocking of cell migration in CW9019 and RH30 cell lines. Conclusion: T.

Leave a Reply